Eurofins-Cerep SA

Eurofins-Cerep SA

EEURONEXT:ALECR
18,400.00
EUR
+300.00
(+1.66%)
86.76MMarket Cap
Eurofins-Cerep SA
EURONEXT:ALECR
(Euronext)

Recent

price

18,400.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
4,794.81
4,609.83
3,685.17
3,978.92
3,669.78
4,463.6
4,646.71
5,158.49
5,046.25
6,147.55
6,476.44
8,250.75
9,442.59
8,737
8,020.87
8,123.52
- -
Revenue per Share
-1,071.77
-15.66
62.85
-175.01
-98.16
358.53
492.86
813.61
764.98
866.43
1,105.73
1,951.38
2,284.78
1,514.43
1,418.43
948.15
- -
Basic EPS, GAAP
-379.06
471.05
55.71
-437.03
-700.66
-102.56
5.55
671.17
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2,703.01
2,689.73
2,762.49
2,707.33
2,610.76
2,967.74
3,460.94
4,224.15
4,989.05
5,855.4
6,961.05
8,995.88
11,286.65
12,810.2
14,222.85
15,163.19
16,112.81
Book Value per Share
2,626.88
2,629.46
2,721.05
2,692.1
2,593.73
2,964.99
3,407.41
4,171.13
4,936.23
5,406.55
6,518.17
8,552.99
10,843.76
12,367.31
13,739.93
14,705.05
15,644.92
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
24
23
19
20
18
23
23
24
25
31
33
42
48
44
40
41
- -
Sales/Revenue/Turnover
-12.67
4
9.4
0.02
29.32
4.38
6.96
15.54
19.17
14.12
17.78
24.27
24.61
14.63
10.96
8.75
- -
Operating Margin (%)
2
2
1
1
- -
1
-1
- -
1
1
1
1
2
2
2
2
- -
Depreciation Expense
-5
- -
- -
-1
- -
2
2
4
4
4
6
10
12
8
7
5
- -
Net Income, GAAP
- -
12.37
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-22.35
-0.34
1.71
-4.4
-2.67
8.03
10.61
15.77
15.16
14.09
17.07
23.65
24.2
17.33
17.68
11.67
- -
Profit Margin (%)
15
6
6
15
14
15
15
19
22
24
29
36
46
53
62
69
74
Working Capital
4
3
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
14
14
14
14
13
15
17
21
25
30
35
45
57
65
72
76
81
Total Equity
- -
3.32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
0.79
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-33.23
-0.58
2.31
-6.44
-3.69
12.86
15.33
19.86
16.61
15.98
17.25
24.46
22.53
12.57
10.49
6.45
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
104
90
87

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
74
79
83
Cash, Cash Equivalents & STI
14
21
19
Accounts Receivable, Net
8
8
8
Inventories
3
3
3
Total Current Liabilities
9
10
9
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.89%
17.17%
6.61%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
15.38%
4.07%
-33.15%
Sales/Revenue/Turnover
6.72%
5.49%
1.28%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
40
2025
- -
- -
41
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1,418.43
2025
- -
- -
948.15
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Eurofins-Cerep SA provides drug discovery services, including compound management, high-throughput screening, profiling, in vitro pharmacology, in vitro ADME-Tox studies, and in vivo pharmacokinetic services, to pharmaceutical, biopharmaceutical, and biotechnology companies in France and internationally. Founded in 1989 and headquartered in Celle-Lévescault, France, the company operates as a subsidiary of Eurofins Discovery Services LUX Holding SARL, following its name change from Cerep SA in June 2014. Eurofins-Cerep specializes in pre-clinical research solutions for drug development, with exports accounting for the majority of its net sales.